Skip to main content

Table 1 Main characteristics of all the studies included in the meta-analysis (no. = 3338)

From: Prognostic value of lymphocyte to monocyte ratio in pancreatic cancer: a systematic review and meta-analysis including 3338 patients

Author Year Country Ethnicity No. (M/F) Follow-up (months) (median and range) Treatment Age (years; mean ± SD) Cut-off value Outcome Stage Type Variable type NOS score
Manabu et al. [30] 2019 Japan Asian 67 (40/27) NR Mix 68 (46–80) 4 OS IIa–III PC UV 6
Shinichi et al. [34] 2019 Japan Asian 136 (76/60) 16.8 (1.3–104.3) Surgery 68 (33–86) 4.6 OS I–IV PDAC UV 5
Toshiya et al. (1) [29] 2018 Japan Asian 329 (131/198) NR Surgery 67 (61–74) 3 OS/DFS 0–III PDAC UV 5
Toshiya et al. (2) [29] 2018 Japan Asian 95 (39/56) NR Surgery 65 (58–69) 3 OS PDAC UV/MV 5
Sierzega et al. [40] 2017 Poland Caucasian 442 (182/260) 93 (15–290) Surgery 60 (55–66) 3 OS IA–III PDAC UV/MV 5
Singh et al. [27] 2017 USA Mixed 97 (97/0) NR Mixed 66 ± 0.9 2.05 OS I–IV PDAC UV 6
Xue et al. (1) [39] 2017 China Asian 153 (102/51) 8.8 (0.5–75.5) Chemotherapy 60 (34–86) 2.8 OS III–IV PDAC UV/MV 6
Xue et al. (2) [39] 2017 Japan Asian 252 (133/119) NR Chemotherapy 67 (31–86) 2.8 OS III–IV PDAC UV/MV 6
Yu et al. (1) [38] 2017 China Asian 139 (83/56) 78 Chemotherapy < 60, 54
≥ 60, 85
3.19 OS III–IV PDAC UV/MV 5
Yu et al. (2) [38] 2017 China Asian 225 (146/79) 78 Chemotherapy < 60, 78
≥ 60, 147
3.19 OS III–IV PDAC UV/MV 5
Li et al. [26] 2016 China Asian 144 (77/67) 14 (6–40) Surgery 62 ± 2.8 2.86 OS/RFS I–III PDAC UV/MV 6
Qi et al. (1) [31] 2016 China Asian 177 (108/69) NR Chemotherapy 58.8 ± 10.7 3 OS/TTP III–IV PDAC UV/MV 6
Qi et al. (2) [31] 2016 China Asian 321 (208/113) NR Chemotherapy 61.0 ± 10.1 3 OS/TTP III–IV PDAC UV/MV 6
Qi et al. (3) [31] 2016 China Asian 76 (46/30) NR Chemotherapy 60.9 ± 9.6 3 OS/TTP III–IV PDAC UV/MV 6
Qi et al. [37] 2015 China Asian 211 (134/77) NR Chemotherapy 61.2 ± 10.7 3.33 OS III–IV PDAC UV/MV 6
Stotz et al. [28] 2015 Austria Caucasian 474 (256/218) 36 (0–162) Mix 64.6 ± 10.4 2.8 OS I–IV PDAC UV/MV 6
  1. OS overall survival, PFS progression-free survival, DFS disease-free survival, HR hazard ratio, obtained by reporting in text (R), MV the HR come from multivariate analysis, UV the HR comes from univariate analysis; Mix mixed treatment including chemotherapy, surgery, and radiotherapy, NR not reported, NOS Newcastle–Ottawa Quality Assessment Scale, PDA pancreatic ductal adenocarcinoma